Suppressive potencies of calcineurin inhibitors against the mitogen‐induced blastogenesis of peripheral‐blood mononuclear cells of myasthenia gravis patients
暂无分享,去创建一个
[1] M. García-Carrasco,et al. Therapeutic options in autoimmune myasthenia gravis. , 2007, Autoimmunity reviews.
[2] K. Oka,et al. P-glycoprotein function in peripheral blood mononuclear cells of myasthenia gravis patients treated with tacrolimus. , 2007, Biological & pharmaceutical bulletin.
[3] A. Iyoda,et al. Does perioperative high-dose prednisolone have clinical benefits for generalized myasthenia gravis? , 2006, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[4] Y. Richaud-Patin,et al. Multidrug resistance-1 (MDR-1) in autoimmune disorders IV. P-glycoprotein overfunction in lymphocytes from myasthenia gravis patients. , 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[5] E. Soto-Vega,et al. P-glycoprotein in autoimmune diseases. , 2003, Autoimmunity reviews.
[6] H. Geiger,et al. Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients. , 2001, Kidney international.
[7] G. Plosker,et al. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. , 2000, Drugs.
[8] K. Oka,et al. Individual variations in lymphocyte-responses to glucocorticoids in patients with bronchial asthma: comparison of potencies for five glucocorticoids. , 1998, Immunopharmacology.
[9] K. Oka,et al. Immunosuppressant pharmacodynamics on lymphocytes from healthy subjects and patients with chronic renal failure, nephrosis, and psoriasis: Possible implications for individual therapeutic efficacy , 1997, Clinical pharmacology and therapeutics.
[10] K. Goa,et al. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. , 1997, Drugs.
[11] K. Oka,et al. Clinical significance of glucocorticoid pharmacodynamics assessed by antilymphocyte action in kidney transplantation. Marked difference between prednisolone and methylprednisolone. , 1994, Transplantation.
[12] S. Bourgeois,et al. Expression of an mdr gene is associated with a new form of resistance to dexamethasone-induced apoptosis. , 1993, Molecular endocrinology.
[13] Y. Tanigawara,et al. Human P-glycoprotein transports cyclosporin A and FK506. , 1993, The Journal of biological chemistry.
[14] I. Roninson,et al. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. , 1992, Blood.
[15] A. B. Kay,et al. Lymphocytes , 1991 .
[16] D. Elmqvist. Myasthenia Gravis , 1975, The Lancet.
[17] T. Hirano. Cellular pharmacodynamics of immunosuppressive drugs for individualized medicine. , 2007, International immunopharmacology.
[18] M. Baba,et al. Favorable results of thymectomy combined with prednisolone alternate-day administration in myasthenia gravis , 2006, The Japanese journal of surgery.
[19] M. Okuhara,et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. , 1987, The Journal of antibiotics.